Vansteenkiste Johan, Fischer Barbara M, Dooms Christophe, Mortensen Jann
Clinical Trial Unit, Department of Pulmonology, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium.
Lancet Oncol. 2004 Sep;5(9):531-40. doi: 10.1016/S1470-2045(04)01564-5.
Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis and staging of lung cancer, but is also appealing for assessment of prognosis and treatment. A systematic search of the published work shows good evidence that [(18)F]FDG uptake on PET has independent prognostic value in newly diagnosed non-small-cell lung cancer. PET is a sensitive method of measuring the biological effects of anticancer therapy, but until better standardisation and large-scale experience is available, it should only be used for additional assessments of early response in clinical trials. Further studies are needed to define the role of [(18)F]FDG-PET in restaging after induction therapy in multimodality approaches for locally advanced lung cancer. The assessment of prognosis by [(18)F]FDG-PET is less substantiated in treated lung cancer than in newly diagnosed patients. Good prospective evidence documents the effectiveness of [(18)F]FDG-PET over CT in the correct identification of recurrent lung cancer.
18氟脱氧葡萄糖正电子发射断层扫描（PET）在肺癌的诊断和分期中发挥着作用，同时在预后评估和治疗方面也具有吸引力。对已发表研究的系统检索表明，有充分证据显示PET上的[（18）F]FDG摄取在新诊断的非小细胞肺癌中具有独立的预后价值。PET是一种测量抗癌治疗生物学效应的敏感方法，但在获得更好的标准化和大规模经验之前，它仅应用于临床试验中早期反应的额外评估。需要进一步研究来确定[（18）F]FDG-PET在局部晚期肺癌多模式治疗诱导治疗后再分期中的作用。与新诊断患者相比，[（18）F]FDG-PET对治疗后肺癌预后的评估依据不足。良好的前瞻性证据证明了[（18）F]FDG-PET在正确识别复发性肺癌方面优于CT。
